Antibe Therapeutics (TSX:ATE) Equity-to-Asset : 0.46 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Antibe Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$25.94 Mil. Antibe Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was C$56.36 Mil.

The historical rank and industry rank for Antibe Therapeutics's Equity-to-Asset or its related term are showing as below:

TSX:ATE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27 Med: 0.54 Max: 0.85
Current: 0.46

During the past 12 years, the highest Equity to Asset Ratio of Antibe Therapeutics was 0.85. The lowest was 0.27. And the median was 0.54.

TSX:ATE's Equity-to-Asset is ranked worse than
66.96% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs TSX:ATE: 0.46

Antibe Therapeutics Equity-to-Asset Historical Data

The historical data trend for Antibe Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Equity-to-Asset Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Equity-to-Asset

Get a 7-Day Free Trial

0.50

0.27

0.62

0.64

0.57

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.59	0.57	0.52	0.49	0.46

Competitive Comparison of Antibe Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Antibe Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Equity-to-Asset falls into.

Antibe Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Antibe Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	40.166	/	70.561
	=

Antibe Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	25.937	/	56.362
	=

Antibe Therapeutics (TSX:ATE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Antibe Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines